Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Ezabenlimab (BI 754091) plus modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) followed by chemoradiotherapy (CRT) in patients (pts) with stage III squamous cell anal carcinoma (SCCA): Early efficacy endpoint results from the phase II INTERACT-ION study.
Authors
Stefano Kim
Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon, Besançon, France; Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France; INSERM, Unit 1098, University of Bourgogne Franche-Comté, Besançon, France
Stefano Kim , Jihane Boustani , Dewi Vernerey , Ludovic Evesque , Benoist Chibaudel , Angélique Vienot , Olivier Bouche , Chloé Vernet , Clélia Coutzac , François Ghiringhelli , David Tougeron , Laurent Quero , Laurent Mineur , Aurelién Carnot , Aurelia Meurisse , Magali Rebucci-Peixoto , Sarah Chennoufi , Christophe Maritaz , Christophe Borg
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04719988
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 2)
DOI
10.1200/JCO.2024.42.3_suppl.2
Abstract #
2
Poster Bd #
B12
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with stage 3 squamous cell anal carcinoma: INTERACTION phase II study.
First Author: Stefano Chong Hun Kim
Poster
2023 ASCO Annual Meeting
Atezolizumab plus tiragolumab in combination with chemoradiotherapy in localized squamous cell carcinoma of the anal canal: TIRANUS (GEMCAD-2103) trial.
First Author: Jaume Capdevila
Poster
2014 ASCO Annual Meeting
Randomized phase II trial of weekly paclitaxel, carboplatin, cetuximab (PCC) versus cetuximab, docetaxel, cisplatin, and fluorouracil (C-TPF) in previously untreated patients with locally advanced head and neck squamous cell carcinoma.
First Author: Erminia Massarelli
Poster
2012 Gastrointestinal Cancers Symposium
Preliminary result of a multicenter phase II study of chemoradiotherapy with docetaxel for elderly patients with stage II/III esophageal carcinoma.
First Author: Jun Hashimoto